ClinicalTrials.gov
public full text
Public Domain
BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction
The purpose of this registry (NCT02880618) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction#845874
- BAROSTIM THERAPY™ In Resistant Hypertension#1086057
- Skeletal Muscle Dysfunction in Heart Failure with Preserved Ejection Fraction / Beatrice Vahle ; Gutachter: Volker Adams, Martin Bahls#669405
- What about chronotropic incompetence in heart failure with mildly reduced ejection fraction? Clinical and prognostic implications from the Metabolic Exercise combined with Cardiac and Kidney Indexes score dataset#250610
- Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)#1352681
Record · ID 1282947
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive